Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05116540 · ClinicalTrials.gov registry record · Phase 2
Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis
A Phase 2 study, sponsored by Hope Biosciences Research Foundation.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT05116540 is a Phase 2 study that has completed, run by Hope Biosciences Research Foundation. The registered enrollment target is 24 participants.
The verdict
NCT05116540, a Phase 2 study, has completed, sponsored by Hope Biosciences Research Foundation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
Randomized Double-Blind Efficacy and safety study of Autologous HB-adMSCs versus placebo for the treatment of Multiple Sclerosis. This study will be for 24 subjects with 6 infusions over a 52 week period. Study participants will continue their established concomitant medications during participation in this investigation.
Interventions
- DRUG Placebo
- BIOLOGICAL HB-adMSCs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2021-11-24 |
| Est. Completion | 2024-06-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05116540
The ClinicalTrials.gov registry entry for NCT05116540 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hope Biosciences Research Foundation, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05116540 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05116540 about?
NCT05116540 is a clinical study titled "Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis". Randomized Double-Blind Efficacy and safety study of Autologous HB-adMSCs versus placebo for the treatment of Multiple Sclerosis. This study will be for 24 subjects with 6 infusions over a 52 week period. Study participants will continue their established concomitant medications during participation...
What is the current status of trial NCT05116540?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2021-11-24. Estimated completion is 2024-06-04.
What interventions are being tested in trial NCT05116540?
The interventions under investigation include: Placebo (DRUG), HB-adMSCs (BIOLOGICAL).
Who is sponsoring clinical trial NCT05116540?
This trial is sponsored by Hope Biosciences Research Foundation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.